India: Developing Biosimilars In India: Prescriptions And Problems

Last Updated: 6 November 2014
Article by Priya Anuragini

In India, access to health care facilities is still limited to a very small percentage of population owing mostly to unavailability of affordable drugs and treatment. Surprisingly, this predicament has persisted despite the presence of strong and competent generic pharmaceutical industry which hitherto has been fully supported by both government policies and statutory framework in its endeavour to provide drugs as cheaply as possible. As India looks for newer avenues to meet the healthcare needs of its huge 1.2 billion population "Biosimilars" or "Similar Biologics" represent significant potential.

What exactly are Biosimilars?

"Biosimilars" are similar versions of innovator pharmaceutical product, though not their generic equivalents, which are marketed after the expiration of the patent. As an enormous no. of pharmaceutical patents are expiring in the coming years, biosimilar industry is sure to grow and its capability to produce affordable biotech medicines would further expand. And to ensure optimum development and growth of the market for biosimilars in India, Indian government has already issued "Guidelines on Similar Biologics: Regulatory requirements for market authorization in India" in the year 2012 which lays down specific standards for development and evaluation of similar biologics in India. These guidelines seek to ensure comparability of safety, efficacy and quality between the innovator biologic product and the biosimilar. Since biosimilar products are not identically similar to the reference innovator product, any variation needs to be assessed in detail to ensure that there is no therapeutic consequence for the patient. This essentially means that biosimilar developers do not only have to perform clinical trials on the newly developed biosimilar drug but also on the original product and compare the data to ensure efficacy and safety. The determination that the biosimilar product is similar to the original biologic in terms of structural characteristics, safety, efficacy and quality can only be made after careful scrutiny of analytical, clinical and non-clinical data. Accordingly, biosimilars require a comprehensive evaluation before they can be safely marketed and that is sought to be achieved by the above mentioned guidelines which establish appropriate regulatory pathways to ensure cost effective and safe production of biosimilars in India.

Before Biosimilars can be marketed- Crossing the regulatory threshold

All the biosimilars whether manufactured in India or imported into the country have to follow a multi-step procedure to get marketing authorization in India. The regulatory bodies responsible for approval of 'similar biologics' in India are the: Department of Biotechnology (DBT) under the Ministry of Science and Technology through its Review Committee on Genetic Manipulation (RCGM) and the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare.

The starting point of the regulatory framework enunciates that a similar biologic can be developed in India only if the reference biologic chosen is a licensed innovator product in India. If the reference biologic is not a licensed or marketed innovator product in India then it should have been licensed and marketed for minimum of 4 years post approval in innovator's jurisdiction having well established regulatory framework. Only when this fundamental criterion is fulfilled the multi-step approval process can be initiated.

In the first step of approval, applicant is permitted to conduct studies with the reference biologic so as to generate information regarding manufacturing processes and product characterization. Once the applicant generates the above information, it is submitted along with basic clinical information and preclinical study protocols to the RCGM. In the second step applicant receives the approval to conduct pre- clinical trials which again requires a no. of studies to be made. After the successful evaluation of preclinical study reports, in the third step approval for clinical trials is given. Once all the clinical studies have been successfully completed, in the fourth step applicant can submit an application for market authorization to DGCI (Drug Controller General of India). Once the applicant receives marketing authorization, the similar biologic can be sold in India. Once such marketing authorization is received, the Applicant is required to submit a post-marketing risk management plan.

Important lessons from Roche-Biocon Lawsuit

As is clearly evident the approval process required to develop similar biologics in India stipulates compliance with a long prescribed procedure and would essentially require a significant period of time. Interestingly in one of the recent pharmaceutical lawsuits before Delhi High Court wherein Roche sued Indian pharmaceutical company Biocon and US based global generic Mylan for launching first biosimilar version of its original cancer drug "Herceptin" in India, one of the major contentions of Roche was that launch of "CANMAB" which was said to be biosimilar version of Roche's Herceptin was not in accordance with the guidelines prescribed for similar biologics. After all, what the guidelines prescribe is a long process. However drug was approved by DGCI in considerably short period of time. Moreover there was no public record to show that clinical trials were actually conducted before the drug was approved. Considering that the procedure for approval is multi –step requiring a lot of time, approval for the drug could not have been granted legally in such short span of time by the Drug Controller, Roche claimed. And in absence of compliance with due procedure for approval and non-conduct of appropriate tests the drug cannot be regarded as a biosimilar version and was being misrepresented as such in order to pass off the drug as being of same quality and reputation as Roche's Herceptin . Delhi High Court, accordingly restrained Biocon and Mylan from launching CANMAB without requisite approvals emphasizing the importance of following the prescribed procedure before a biosimilar drug can be sold in the market.

Concerns of Generic manufacturers

At this juncture, India certainly needs cost effective production of biosimilars in order to effectively address its health concerns and detailed and structured guidelines by the Government in this direction are indeed welcome. However, the high threshold of regulatory guidelines coupled with technical requirements and the risk of patent infringement litigation acts as a major deterrent for the generic manufacturers who want express commitment from the government that once they invest in something as complex as biosimilars, they would be allowed to launch it. Many of them have even suggested that a compulsory license be granted prior to development of biosimilars. In view of international obligations this may not always be possible and it's important for the government to alleviate the concerns of the biosimilar developers without comprising on the regulatory compliance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.